Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IAPT

- PMLiVE

NICE’s long-serving chief exec Sir Andrew Dillon to step down

Pharma leader praises "laser focus" on thorny access questions

- PMLiVE

NICE’s fast-track catapults Skyrizi into market

Watchdog also gives direction on comparing rival treatments

A uniquely English genomic medicine service

The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...

Blue Latitude Health

- PMLiVE

Additional investment ‘desperately needed’ as NHS performance figures show record highs

A&E attendances at record numbers

- PMLiVE

Boris pledges a £1.8bn cash injection for the NHS

Annual budget will increase 30%

- PMLiVE

Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

Deal done with NHS England just weeks after EU approval

Diagnosing the lag in neuropsychiatric treatments

The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop...

Blue Latitude Health

- PMLiVE

NICE unveils long-awaited review of methodologies

Use of quality of life measures to be reviewed

- PMLiVE

Kisqali combination follows Verzenio onto Cancer Drugs Fund

Drug must prove its value via managed access route

- PMLiVE

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

New fast-track appraisal a boon for companies

- PMLiVE

UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D

Pilot much more to industry liking, but devil will be in detail

- PMLiVE

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

Acknowledges unmet need

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links